

Application No. 10/643,404
 Amendment dated August 2, 2006
 Reply to Office Action of April 20, 2006

2

Docket No.: 59753(48185)


RECEIVED
 CENTRAL FAX CENTER

AUG 2 2006

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

1. (Currently amended) A method for prevention and/or therapy of arterial wall injury which is caused by coronary angioplasty or coronary-artery bypass graft (CABG), which comprises a step of administering 3-methyl-1-phenyl-2-pyrazolin-5-one the pyrazolone derivative represented by the following formula (I) or the physiologically acceptable salt thereof, or the hydrate or solvate thereof in a preventively or therapeutically effective amount to mammals including humans[[]].



wherein R¹ represents a hydrogen atom, an aryl group, a C₁₋₅ alkyl group, or a C₂₋₆ (total carbon number) alkoxycarbonylalkyl group; R² represents a hydrogen atom, an aryloxy group, an arylmercapto group, a C₁₋₅ alkyl group or a C₁₋₃ hydroxylalkyl group; or R¹ and R² are combined with each other to represent C₂₋₅ alkylene group; and R³ represents a hydrogen atom, a C₁₋₅ alkyl group, a C₃₋₇ cycloalkyl group, a C₁₋₃ hydroxylalkyl group, a benzyl group, a naphthyl group, a phenyl group, or a phenyl group substituted with the same or different 1 to 3 substituents selected from the group consisting of a C₁₋₅ alkyl group, a C₁₋₅ alkoxy group, a C₁₋₃ hydroxylalkyl group, a C₂₋₅ (total carbon number) alkoxycarbonyl group, a C₁₋₃ alkylmercapto group, a C₁₋₄ alkylamino group, a C₂₋₅ (total carbon number) dialkylamino group, a halogen atom, a trifluoromethyl group, a carboxyl group, a cyano group, a hydroxyl group, a nitro group, an amino group and an acetyl group.

2. (Cancelled)

3. (Cancelled)

BEST AVAILABLE COPY

Application No. 10/643,404
Amendment dated August 2, 2006
Reply to Office Action of April 20, 2006

3

Docket No.: 59753(48185)

4. (Currently amended) The method according to claim 1 or 2 wherein the arterial wall injury is restenosis or neointimal formation after percutaneous transluminal coronary angioplasty (PTCA) or coronary-artery bypass graft (CABG).
5. (New) The method according to claim 1 or 4 wherein the coronary angioplasty is percutaneous transluminal coronary angioplasty (PTCA) or percutaneous coronary intervention (PCI).

BEST AVAILABLE COPY